|
Synonyms: IDEC-2B8 | IDEC-Y2B8-yttrium ibritumomab tiuxetan | NSC-715848 | Zevalin®
ibritumomab tiuxetan is an approved drug (FDA (2002), EMA (2004))
Compound class:
Antibody
Comment: A monoclonal antibody used as a radioimmunotherapy treatment.
|
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes (FDA (2002), EMA (2004)) |
| Approved drug? | Yes. FDA (2002) | EMA (2004) |
| International Nonproprietary Names |
|
| INN number | INN |
| 7873 | ibritumomab tiuxetan |
| Synonyms |
| IDEC-2B8 | IDEC-Y2B8-yttrium ibritumomab tiuxetan | NSC-715848 | Zevalin® |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 122 |
| Other databases | |
| GtoPdb PubChem SID | 178103383 |
| PubChem SID | 178103383 |
| Search PubMed clinical trials | ibritumomab tiuxetan |
| Search PubMed titles | ibritumomab tiuxetan |
| Search PubMed titles/abstracts | ibritumomab tiuxetan |
| Wikipedia | Ibritumomab_tiuxetan |
